gsk2798745
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02119260)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(O)c1cnc(N2C[C@@]3(CCC[C@](C)(Cn4cnc5ccc(C#N)cc54)C3)OC2=O)cn1- Mol. weight
- 460.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4470585 ↗
- ChEMBLCHEMBL3707225 ↗
Also known as
- gsk2798745
- gsk2798745
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04292912 | Phase 1 | Mar 9, 2020 | GlaxoSmithKline |
| NCT03511105 | Phase 1 | Jun 25, 2018 | Department of Health and Human Services, GlaxoSmithKline |
| NCT03372603 | Phase 2 | Apr 5, 2018 | Department of Health and Human Services, GlaxoSmithKline |
| NCT02925546 | Phase 1 | Oct 1, 2016 | GlaxoSmithKline |
| NCT02497937 | Phase 2 | Apr 13, 2016 | GlaxoSmithKline |
| NCT02119260 | Phase 1 | Jun 1, 2014 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2014 |
| Department of Health and Human Services | Government | 2 | 0 | 2 | 2018 |
2 organizations
Page 1 / 1